Peter Virsik
Chief Operating Officer chez ESSA PHARMA INC.
Fortune : 101 371 $ au 31/03/2024
Profil
Peter A.
Virsik is currently the Chief Operating Officer & Executive Vice President at ESSA Pharma, Inc. He previously worked as an Associate Director at Gilead Sciences, Inc. from 2000 to 2005 and as the Senior Vice President-Corporate Development at XenoPort, Inc. from 2005 to 2015.
Virsik received his undergraduate degree from the University of California, Berkeley, his graduate degree from the University of Michigan, and his MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ESSA PHARMA INC
0,03% | 05/04/2024 | 11 940 ( 0,03% ) | 101 371 $ | 31/03/2024 |
Postes actifs de Peter Virsik
| Sociétés | Poste | Début |
|---|---|---|
| ESSA PHARMA INC. | Chief Operating Officer | 01/08/2016 |
Anciens postes connus de Peter Virsik
| Sociétés | Poste | Fin |
|---|---|---|
| XENOPORT, INC. | Corporate Officer/Principal | 01/01/2015 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2005 |
Formation de Peter Virsik
| University of California, Berkeley | Undergraduate Degree |
| University of Michigan | Graduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ESSA PHARMA INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
